Johnson & Johnson to Appeal $150 Million Verdict in HIV Meds Off-Label Marketing Case

1. Verdict and Appeal: Johnson & Johnson (J&J) has been ordered to pay $150 million in a whistleblower case dating back to 2012, which involves off-label marketing of HIV medications. The company plans to appeal the verdict.
2. Case Background: The case revolves around J&J's alleged off-label marketing practices for its HIV medications, which led to a guilty verdict in a New Jersey court.
3. Industry Context: This verdict is part of a broader trend of legal challenges faced by biopharma companies, including lawsuits against the Inflation Reduction Act's drug pricing provisions.
4. Industry Reactions: The verdict and subsequent appeal have sparked reactions from industry groups and patient advocacy organizations, highlighting concerns about the impact on innovation and patient access to medications.